Generic Asacol Not Likely in 2013 in the US?

I just read the following from a financial website:

"Actavis (NYSE:ACT): JPMorgan recommends adding to Actavis positions following the modest pullback over the past month. It believes that a generic version of Asacol being approved in 2013 is highly unlikely and sees upside to its 2014 and 2015 estimates. The firm has a $150 price target for shares and keeps an Overweight rating."

Apparently, Actavis is acquiring Warner Chilcott, the maker of Asacol.

That really sucks if it is true, I was hoping for a generic Asacol this year.

I guess it would depend on exactly what the patent was although based on other articles I have read, I do not think the change to delzicol affects the patent. Other articles were speculating if a generic mesalamine would impact the Actavis / Warner Chilcott buy out.

To me, the most frustrating part is that Actavis is mainly in the generic drug market. Now, of course, they have no incentive to work on a generic. Of course, there are other generic makers out there so hopefully we will see a generic approved in 2014.